Cargando…
Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator
Dorzagliatin is a novel allosteric glucokinase activator targeting both pancreatic and hepatic glucokinase currently under clinical investigation for treatment of type 2 diabetes (T2D). This study aimed to investigate the effect of renal impairment (RI) on dorzagliatin’s pharmacokinetics (PKs) and s...
Autores principales: | Miao, Jia, Fu, Ping, Ren, Shuang, Hu, Chao, Wang, Ying, Jiao, Chengfeng, Li, Ping, zhao, Yu, Tang, Cui, Qian, Yuli, Yang, Rong, Dong, Yanli, Rong, Jing, Wang, Yaohui, Jin, Xiaowei, Sun, Yu, Chen, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841463/ https://www.ncbi.nlm.nih.gov/pubmed/34706161 http://dx.doi.org/10.1111/cts.13174 |
Ejemplares similares
-
Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes
por: Chow, Elaine, et al.
Publicado: (2023) -
Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus
por: Wang, Kun, et al.
Publicado: (2023) -
Efficacy and safety of dorzagliatin for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
por: Yu, Yunfeng, et al.
Publicado: (2022) -
Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
por: Yang, Wenying, et al.
Publicado: (2022) -
Preliminary screening of mutations in the glucokinase gene of Chinese patients with gestational diabetes
por: Wang, Zhixin, et al.
Publicado: (2017)